Related references
Note: Only part of the references are listed.The role of dopamine D3receptors in the mechanism of action of cariprazine
Francesca Calabrese et al.
CNS SPECTRUMS (2020)
The dopamine receptor antagonist trifluoperazine prevents phenotype conversion and improves survival in mouse models of glioblastoma
Kruttika Bhat et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Increased dopamine and its receptor dopamine receptor D1 promote tumor growth in human hepatocellular carcinoma
Yan Yan et al.
CANCER COMMUNICATIONS (2020)
ONC201 and imipridones: Anti-cancer compounds with clinical efficacy
Varun Vijay Prabhu et al.
NEOPLASIA (2020)
Dopamine Agonists: From the 1970s to Today
Renata S. Auriemma et al.
NEUROENDOCRINOLOGY (2019)
The Direct Molecular Target for Imipridone ONC201 Is Finally Established
Shaomeng Wang et al.
CANCER CELL (2019)
Cancer and the Dopamine D2 Receptor: A Pharmacological Perspective
Jillian S. Weissenrieder et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2019)
Role of the brain-gut axis in gastrointestinal cancer
Yang-Zi Di et al.
WORLD JOURNAL OF CLINICAL CASES (2019)
Antipsychotic Drug Trifluoperazine Suppresses Colorectal Cancer by Inducing G0/G1 Arrest and Apoptosis
Yong Xia et al.
FRONTIERS IN PHARMACOLOGY (2019)
Selective YAP/TAZ inhibition in fibroblasts via dopamine receptor D1 agonism reverses fibrosis
Andrew J. Haak et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
A Bayesian machine learning approach for drug target identification using diverse data types
Neel S. Madhukar et al.
NATURE COMMUNICATIONS (2019)
Cabergoline in the Management of Residual Nonfunctioning Pituitary Adenoma A Single-Center, Open-Label, 2-Year Randomized Clinical Trial
Rafael L. Batista et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2019)
Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism
Varun V. Prabhu et al.
CLINICAL CANCER RESEARCH (2019)
Calmodulin antagonist enhances DR5-mediated apoptotic signaling in TRA-8 resistant triple negative breast cancer cells
Romone M. Fancy et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2018)
The fibrotic tumor stroma
Mitsuo Yamauchi et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Repositioning Dopamine D2 Receptor Agonist Bromocriptine to Enhance Docetaxel Chemotherapy and Treat Bone Metastatic Prostate Cancer
Yang Yang et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Parkinson's Disease and Melanoma: Co-Occurrence and Mechanisms
Anindita Bose et al.
JOURNAL OF PARKINSONS DISEASE (2018)
Association of Schizophrenia With the Risk of Breast Cancer Incidence A Meta-analysis
Chuanjun Zhuo et al.
JAMA PSYCHIATRY (2018)
Role of Dopamine Receptors in the Anticancer Activity of ONC201
Christina Leah B. Kline et al.
NEOPLASIA (2018)
The antipsychotic agent trifluoperazine hydrochloride suppresses triple-negative breast cancer tumor growth and brain metastasis by inducing G0/G1 arrest and apoptosis
Zhanzhan Feng et al.
CELL DEATH & DISEASE (2018)
Cariprazine, A Dopamine D2/D3 Receptor Partial Agonist, Modulates ABCG2-Mediated Multidrug Resistance in Cancer
Noor Hussein et al.
CANCERS (2018)
The Balance of PI3K and ERK Signaling Is Dysregulated in Prolactinoma and Modulated by Dopamine
Allyson K. Roof et al.
ENDOCRINOLOGY (2018)
A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia
Lili Aslostovar et al.
BLOOD ADVANCES (2018)
Activation of D2 Dopamine Receptors in CD133+ve Cancer Stem Cells in Non-small Cell Lung Carcinoma Inhibits Proliferation, Clonogenic Ability, and Invasiveness of These Cells
Soumyabrata Roy et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
Trifluoperazine, a Well-Known Antipsychotic, Inhibits Glioblastoma Invasion by Binding to Calmodulin and Disinhibiting Calcium Release Channel IP3R
Seokmin Kang et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Stromal microenvironment in type VII collagen-deficient skin: The ground for squamous cell carcinoma development
Liliana Guerra et al.
MATRIX BIOLOGY (2017)
Parkinson Disease and Melanoma: Confirming and Reexamining an Association
Lauren A. Dalvin et al.
MAYO CLINIC PROCEEDINGS (2017)
Current Development Status of MEK Inhibitors
Ying Cheng et al.
MOLECULES (2017)
Lung cancer in patients with idiopathic pulmonary fibrosis
Theodoros Karampitsakos et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2017)
A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma
Isabel Arrillaga-Romany et al.
ONCOTARGET (2017)
The Imipridone ONC201 Induces Apoptosis and Overcomes Chemotherapy Resistance by Up-Regulation of Bim in Multiple Myeloma
Yong-Sheng Tu et al.
NEOPLASIA (2017)
Activation of DRD5 (dopamine receptor D5) inhibits tumor growth by autophagic cell death
Zhi Gen Leng et al.
AUTOPHAGY (2017)
Trifluoperazine Activates FOXO1-Related Signals to Inhibit Tumor Growth in Hepatocellular Carcinoma
Jingwen Jiang et al.
DNA AND CELL BIOLOGY (2017)
A pilot study of cabergoline for the treatment of metastatic breast cancer
Ricardo Costa et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
Expression and therapeutic targeting of dopamine receptor-1 (D1R) in breast cancer
D. C. Borcherding et al.
ONCOGENE (2016)
Identification and validation of the dopamine agonist bromocriptine as a novel therapy for high-risk myelodysplastic syndromes and secondary acute myeloid leukemia
Fabio Giuseppe Liberante et al.
ONCOTARGET (2016)
Inhibition of Dopamine Receptor D4 Impedes Autophagic Flux, Proliferation, and Survival of Glioblastoma Stem Cells
Sonam Dolma et al.
CANCER CELL (2016)
Expression of DRD2 Is Increased in Human Pancreatic Ductal Adenocarcinoma and Inhibitors Slow Tumor Growth in Mice
Pouria Jandaghi et al.
GASTROENTEROLOGY (2016)
Associations between cancer and Parkinson's disease in US elderly adults
D. Michal Freedman et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2016)
Repositioning of bromocriptine for treatment of acute myeloid leukemia
Maria Carmen Lara-Castillo et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2016)
Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression
Hanane Laklai et al.
NATURE MEDICINE (2016)
ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2α kinases
C. Leah B. Kline et al.
SCIENCE SIGNALING (2016)
ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies
Jo Ishizawa et al.
SCIENCE SIGNALING (2016)
Discovery and clinical introduction of first-in-class imipridone ONC201
Joshua E. Allen et al.
ONCOTARGET (2016)
ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2α kinases
C. Leah B. Kline et al.
SCIENCE SIGNALING (2016)
ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies
Jo Ishizawa et al.
SCIENCE SIGNALING (2016)
Cabergoline or bromocriptine for prolactinoma?
Nicolas Triantafilo et al.
MEDWAVE (2016)
Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner
Varun V. Prabhu et al.
CANCER RESEARCH (2015)
Dopamine is a safe antiangiogenic drug which can also prevent 5-fluorouracil induced neutropenia
Chandrani Sarkar et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway
Joshua E. Allen et al.
MOLECULAR CANCER (2015)
Sympathoadrenergic modulation of hematopoiesis: a review of available evidence and of therapeutic perspectives
Marco Cosentino et al.
Frontiers in Cellular Neuroscience (2015)
Identification of thioridazine, an antipsychotic drug, as an antiglioblastoma and anticancer stem cell agent using public gene expression data
H-W Cheng et al.
CELL DEATH & DISEASE (2015)
Calmodulin antagonists promote TRA-8 therapy of resistant pancreatic cancer
Kaiyu Yuan et al.
ONCOTARGET (2015)
Timed Bromocriptine-QR Therapy Reduces Progression of Cardiovascular Disease and Dysglycemia in Subjects with Well-Controlled Type 2 Diabetes Mellitus
Bindu Chamarthi et al.
JOURNAL OF DIABETES RESEARCH (2015)
Association Between Parkinson Disease and Risk of Cancer in Taiwan
Pei-Ying Lin et al.
JAMA ONCOLOGY (2015)
Dopamine receptors - IUPHAR Review 13
Jean-Martin Beaulieu et al.
BRITISH JOURNAL OF PHARMACOLOGY (2015)
Cancer Mortality in People Treated with Antidepressants before Cancer Diagnosis: A Population Based Cohort Study
Yuelian Sun et al.
PLOS ONE (2015)
Short-hairpin RNA library: identification of therapeutic partners for gefitinib-resistant non-small cell lung cancer
Makoto Sudo et al.
ONCOTARGET (2015)
Repurposing the Antipsychotic Trifluoperazine as an Antimetastasis Agent
Ashleigh Pulkoski-Gross et al.
MOLECULAR PHARMACOLOGY (2015)
Dopamine d1-like receptors suppress proliferation of vascular smooth muscle cell induced by insulin-like growth factor-1
Xun Kou et al.
CLINICAL AND EXPERIMENTAL HYPERTENSION (2014)
Genome-wide shRNA screen revealed integrated mitogenic signaling between dopamine receptor D2 (DRD2) and epidermal growth factor receptor (EGFR) in glioblastoma
Jie Li et al.
ONCOTARGET (2014)
Dopamine D1 Receptor Signaling: Does GαQ-Phospholipase C Actually Play a Role?
Sang-Min Lee et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
Inverse association between cancer risks and age in schizophrenic patients: A 12-year nationwide cohort study
Chun-Yuan Lin et al.
CANCER SCIENCE (2013)
Each Individual Isoform of the Dopamine D2 Receptor Protects from Lactotroph Hyperplasia
Daniela Radl et al.
MOLECULAR ENDOCRINOLOGY (2013)
Dual Inactivation of Akt and ERK by TIC10 Signals Foxo3a Nuclear Translocation, TRAIL Gene Induction, and Potent Antitumor Effects
Joshua E. Allen et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Dopamine-3 receptor modulates intraocular pressure: Implications for glaucoma
Claudio Bucolo et al.
BIOCHEMICAL PHARMACOLOGY (2012)
Identification of Drugs Including a Dopamine Receptor Antagonist that Selectively Target Cancer Stem Cells
Eleftherios Sachlos et al.
CELL (2012)
A gene signature-based approach identifies thioridazine as an inhibitor of phosphatidylinositol-3 '-kinase (PI3K)/AKT pathway in ovarian cancer cells
Seung Bae Rho et al.
GYNECOLOGIC ONCOLOGY (2011)
Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline
Shlomo Melmed et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
The Physiology, Signaling, and Pharmacology of Dopamine Receptors
Jean-Martin Beaulieu et al.
PHARMACOLOGICAL REVIEWS (2011)
Increased Melanoma Risk in Parkinson Disease A Prospective Clinicopathological Study
John M. Bertoni et al.
ARCHIVES OF NEUROLOGY (2010)
Genetic polymorphisms in folate and alcohol metabolism and breast cancer risk: a case-control study in Thai women
Suleeporn Sangrajrang et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Parkinson's disease and cancer risk: a systematic review and meta-analysis
Archna Bajaj et al.
CANCER CAUSES & CONTROL (2010)
Cancer risk in association with Parkinson disease: A population-based study
Claudia Becker et al.
PARKINSONISM & RELATED DISORDERS (2010)
Getting specialized: presynaptic and postsynaptic dopamine D2 receptors
Claudia De Mei et al.
CURRENT OPINION IN PHARMACOLOGY (2009)
Dopamine D-2 receptor polymorphisms and adenoma recurrence in the Polyp Prevention Trial
Gwen Murphy et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Family history of melanoma and Parkinson disease risk
X. Gao et al.
NEUROLOGY (2009)
TSH-secreting adenoma improved with cabergoline
F. Mouton et al.
ANNALES D ENDOCRINOLOGIE (2008)
Blood pressure and renal sodium handling in relation to genetic variation in the DRD1 promoter and GRK4
Jan A. Staessen et al.
HYPERTENSION (2008)
Dopamine regulates endothelial progenitor cell mobilization from mouse bone marrow in tumor vascularization
Debanjan Chakroborty et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Are Parkinson disease patients protected from some but not all cancers?
Rivka Inzelberg et al.
NEUROLOGY (2007)
Malignant melanoma and other types of cancer preceding Parkinson disease
Jorgen H. Olsen et al.
EPIDEMIOLOGY (2006)
Polymorphisms of the dopamine receptor gene DRD2 and colorectal cancer risk
F Gemignani et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2005)
Risk of cancer after the diagnosis of Parkinson's disease: A historical cohort study
A Elbaz et al.
MOVEMENT DISORDERS (2005)
Atypical cancer pattern in patients with Parkinson's disease
JH Olsen et al.
BRITISH JOURNAL OF CANCER (2005)
Complexity of the bi-directional neuroimmune junction in the spleen
RH Straub
TRENDS IN PHARMACOLOGICAL SCIENCES (2004)
Depleted dopamine in gastric cancer tissues: Dopamine treatment retards growth of gastric cancer by inhibiting angiogenesis
D Chakroborty et al.
CLINICAL CANCER RESEARCH (2004)
Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor
JB Duan et al.
HUMAN MOLECULAR GENETICS (2003)
Cardiotoxicity and prescription of thioridazine in New Zealand
DB Menkes et al.
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY (2002)
Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth
D Lyden et al.
NATURE MEDICINE (2001)
The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor
S Basu et al.
NATURE MEDICINE (2001)
Distinct functions of the two isoforms of dopamine D2 receptors
A Usiello et al.
NATURE (2000)
Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans:: a clinical PET study
S Silvestri et al.
PSYCHOPHARMACOLOGY (2000)
Dopamine D1 receptor gene polymorphism is associated with essential hypertension
M Sato et al.
HYPERTENSION (2000)
Role of dopamine in malignant tumor growth
S Basu et al.
ENDOCRINE (2000)
Mortality and cancer incidence in patients with Parkinson's disease
Y Minami et al.
JOURNAL OF NEUROLOGY (2000)
Share Paper
